5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine

• ChemBase ID: 579
• Molecular Formular: C9H8ClN5S
• Molecular Mass: 253.71132
• Monoisotopic Mass: 253.01889396
• SMILES: Clc1c(NC2=NCCN2)c2nsnc2cc1
• Canonical SMILES: Clc1ccc2c(c1NC1=NCCN1)nsn2
• InChI: InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)
• InChIKey: XFYDIVBRZNQMJC-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
• IUPAC Traditional name: tizanidine
• Brand Name: Sirdalud; Ternelin; Zanaflex
• Synonyms: Tizanidina [INN-Spanish]; Tizanidine Hcl; Tizanidinum [INN-Latin]; Tizanidine; 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3-benzothiadiazole-4-amine

Database IDs

• CAS Number: 51322-75-9
• PubChem SID: 160964042; 46505373
• PubChem CID: 5487

CALCULATED PROPERTIES

JChem

• H Acceptors: 5
• H Donor: 2
• LogD (pH = 5.5): 0.16535637
• LogD (pH = 7.4): 1.6758085
• Log P: 2.024673
• Molar Refractivity: 64.7664 cm^3
• Polarizability: 24.50533 Å^3
• Polar Surface Area: 62.2 Å^2
• Rotatable Bonds: 1
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 1.6
• LOG S: -3.28
• Solubility (Water): 1.33e-01 g/l

PROPERTIES

Physical Property

• Hydrophobicity(logP): 1.4

Product Information

• Purity: 97%

DETAILS

DrugBank - DB00697

• Drug Groups: approved
• Description: Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.
• Indication: For the management of increased muscle tone associated with spasticity
• Pharmacology: Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.
• Affected Organisms: Humans and other mammals
• Half Life: 2.5 hours
• Protein Binding: 30%
• Elimination: Approximately 95% of an administered dose is metabolized.
• Distribution: * 2.4 L/kg
• External Links: Wikipedia; RxList; Drugs.com